S
Susan G. Arbuck
Researcher at Aventis Pharma
Publications - 4
Citations - 18068
Susan G. Arbuck is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Response Evaluation Criteria in Solid Tumors & Pharmacokinetics. The author has an hindex of 3, co-authored 4 publications receiving 17563 citations.
Papers
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
New guidelines to evaluate the response to treatment in solid tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: In this article, the authors proposed a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment.
Journal ArticleDOI
Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion
Michelle A. Rudek,Kenneth S. Bauer,Richard Lush,Sherman F. Stinson,Adrian M. Senderowicz,Donna Headlee,Susan G. Arbuck,Michael C. Cox,Anthony J. Murgo,Edward A. Sausville,William D. Figg +10 more
TL;DR: The dose-limiting toxicity for the Phase I trial of flavopiridol was secretory diarrhea, and a clear relationship between dose or concentration and diarrhea was failed to identify.
Book ChapterDOI
Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets
Edward L. Korn,Larry Rubinstein,Sally Hunsberger,James M. Pluda,Elizabeth Eisenhauer,Susan G. Arbuck +5 more
TL;DR: The chapter explores whether or not it is possible to design a study with enough patients at a dose level to ensure with high probability that after observing the responses one can be 90% confident that the true response rate is greater than some specified level.